Investigating a drug to prevent hearing loss caused by cancer treatment
Preclinical evaluation of an otoprotectant TT002
This study is testing a new drug called TT002 to see if it can help prevent hearing loss caused by cisplatin, a chemotherapy drug that many cancer patients use, so that patients can keep their hearing while still getting the cancer treatment they need.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ting Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Diego, UNITED STATES) |
| Project ID | NIH-11228821 on NIH RePORTER |
What this research studies
This research focuses on developing TT002, a drug that aims to protect against hearing loss induced by cisplatin, a common chemotherapy agent. Cisplatin is effective in treating cancer but can lead to significant hearing loss in a large percentage of patients. The study involves both in vitro and in vivo testing to evaluate the effectiveness of TT002 in preventing this side effect without compromising the drug's cancer-fighting abilities. Patients may benefit from this research as it seeks to provide a solution for a common and distressing complication of cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are being treated with cisplatin and are at risk of hearing loss.
Not a fit: Patients who are not undergoing cisplatin treatment or those who do not experience hearing loss as a side effect of their cancer therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that prevents hearing loss in cancer patients undergoing cisplatin therapy.
How similar studies have performed: While there have been various approaches to prevent cisplatin-induced hearing loss, the specific use of TT002 is novel and has not been extensively tested in this context.
Where this research is happening
San Diego, UNITED STATES
- Ting Therapeutics, INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Huang, Yunlong — Ting Therapeutics, INC.
- Study coordinator: Huang, Yunlong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.